ERYTECH Pharma S.A.
Developing phage therapies to combat antibiotic-resistant bacterial infections.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
PHAXIAM Therapeutics SA, formerly ERYTECH Pharma S.A., is a biopharmaceutical company developing antibacterial treatments based on bacteriophage (phage) therapy. The company focuses on combating bacterial infections, particularly those resistant to antibiotics. Its therapeutic approach utilizes phages—viruses that specifically target and destroy bacteria—to offer a highly targeted treatment for microbial infections, including multi-drug resistant strains. This represents a strategic shift from the company's former focus under the ERYTECH name, which centered on developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-18 07:00 |
Delisting Announcement
Informations privilégiées / Autres communiqués
|
French | 168.4 KB | ||
| 2025-06-18 07:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 169.6 KB | ||
| 2025-06-12 18:00 |
Delisting Announcement
Informations privilégiées / Autres communiqués
|
French | 173.5 KB | ||
| 2025-06-12 18:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 180.8 KB | ||
| 2025-06-05 07:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 116.9 KB | ||
| 2025-06-05 07:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 121.1 KB | ||
| 2025-05-22 18:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 118.8 KB | ||
| 2025-05-22 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 116.6 KB | ||
| 2025-05-05 07:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 118.8 KB | ||
| 2025-05-05 07:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 118.4 KB | ||
| 2025-04-24 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 155.0 KB | ||
| 2025-04-24 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 125.4 KB | ||
| 2025-03-14 17:45 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 168.3 KB | ||
| 2025-03-14 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 172.5 KB | ||
| 2025-03-06 17:56 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 159.2 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
